Using a murine hepatocellular carcinoma development model, Yoshiji and colleagues [9]–[11] showed that combination therapy based on an angiotensin-converting enzyme (ACE) inhibitor (Perindopril [PE]) was able to inhibit angiogenesis mediated by VEGF overexpression. This evidence concerns the gene ACE and hepatocellular carcinoma.